Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VALGANCICLOVIR Cause Interstitial lung disease? 40 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Interstitial lung disease have been filed in association with VALGANCICLOVIR (VALGANCICLOVIR). This represents 0.5% of all adverse event reports for VALGANCICLOVIR.

40
Reports of Interstitial lung disease with VALGANCICLOVIR
0.5%
of all VALGANCICLOVIR reports
14
Deaths
30
Hospitalizations

How Dangerous Is Interstitial lung disease From VALGANCICLOVIR?

Of the 40 reports, 14 (35.0%) resulted in death, 30 (75.0%) required hospitalization, and 7 (17.5%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VALGANCICLOVIR. However, 40 reports have been filed with the FAERS database.

What Other Side Effects Does VALGANCICLOVIR Cause?

Off label use (1,882) Cytomegalovirus infection (1,091) Drug ineffective (886) Neutropenia (809) Leukopenia (574) Drug resistance (524) Cytomegalovirus viraemia (447) Pancytopenia (434) Cytomegalovirus infection reactivation (374) Death (359)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which VALGANCICLOVIR Alternatives Have Lower Interstitial lung disease Risk?

VALGANCICLOVIR vs VALIUM VALGANCICLOVIR vs VALPROATE VALGANCICLOVIR vs VALPROIC ACID VALGANCICLOVIR vs VALPROMIDE VALGANCICLOVIR vs VALSARTAN

Related Pages

VALGANCICLOVIR Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease VALGANCICLOVIR Demographics